Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.44 |
| ▸ | FABP3 | P05413 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25841974 | 0.86 | FABP3 (0.32) | FABP4FABP3FABP5 | |
| SCHEMBL22014385 | 0.86 | FABP3 (0.32) | FABP4FABP3FABP5 | |
| SCHEMBL24783786 | 0.82 | GCGR (0.32) | GABRA1 | |
| SCHEMBL841637 | 0.82 | GABRA1 (0.47) | GABRA1 | |
| SCHEMBL27986405 | 0.80 | FABP4 (0.41) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL24783735 | 0.77 | GLA (0.31) | — | |
| SCHEMBL25138890 | 0.74 | DRD1 (0.34) | — | |
| SCHEMBL19507057 | 0.73 | CHRM2 (0.33) | GABRA1ALDH1A1 | |
| SCHEMBL28217295 | 0.73 | GABRA1 (0.46) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL25219460 | 0.71 | GABRA1 (0.45) | FABP4FABP3FABP5GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| EP-2785714-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Corporation (TW) | 2014-10-08 | — | — | EP | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| EP-2547676-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Inc. (TW) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | FABP4 4405/4885FABP3 4446/4885FABP5 4093/4885 |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | FABP4 4405/4885FABP3 4446/4885FABP5 4093/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | FABP4 4405/4885FABP3 4446/4885FABP5 4093/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | FABP4 4405/4885FABP3 4446/4885FABP5 4093/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | FABP4 4405/4885FABP3 4446/4885FABP5 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.